请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-NDG MHC I/II DKO mice plus
Strain Name 

NOD.CB17-Prkdcscid Il2rgtm1Bcgen B2mtm1Bcgen Fcgrttm1(B2m/Fcgrt)Bcgen H2-Ab1tm1Bcgen/Bcgen


Common Name 

B-NDG MHC I/II DKO mice plus

Background B-NDG mice Catalog number 111895
Aliases 

H2-Ab1: AI845868, Abeta, H-2Ab, H2-Ab, I-Abeta, IAb, Ia-2, Ia2, Rmcs1;
B2m: Ly-m11, beta2-m, beta2m;
Fcgrt: FcRn

Protein expression analysis


from clipboard


Strain specific H-2Kb/H-2Db (MHC-I) and I-Ak (MHC-II) expression analysis in B-NDG mice, B-NDG B2m KO plus mice and B-NDG MHC I/II DKO mice plus by flow cytometry.  Splenocytes were collected from the three mice and analyzed by flow cytometry. Mouse H-2Kb/H-2Db was only detectable in B-NDG mice but not in B-NDG B2m KO plus mice and B-NDG MHC I/II DKO mice plus. Mouse I-Ak was only detectable in B-NDG mice and B-NDG B2m KO plus mice but not in B-NDG MHC I/II DKO mice plus.


Frequency of leukocyte subpopulations in spleen,blood and bone marrow 


from clipboard

Frequency of leukocyte subpopulations in spleen, blood and bone marrow by flow cytometry. Blood, spleen and bone marrow were collected from B-NDG mice and B-NDG MHC I/II DKO mice plus (male, 9-week-old, n=3). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells, B cells and NK cells were not detectable in all tissues of B-NDG mice and B-NDG MHC I/II DKO mice plus. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***p < 0.001. 


Significantly reduced severity of GvHD induced with human PBMC engraftment in B-NDG MHC I/II DKO mice plus

from clipboard


Comparison of the severity of GvHD induced with human PBMC engraftment in B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus. Five weeks old of female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were respectively engrafted intravenously with human PBMCs (5 × 106) from three healthy donors (Donor 1-3) on day 0 (n=5).  A. Survival rates of the mice were analyzed with Kaplan Meier survival curves. B. Body weight changes. C. Clinical signs of GvHD were scored twice a week. Results showed that MHC I/II double knocked-out in B-NDG MHC I/II DKO mice plus can significantly extend the life span and reduced the GvHD induced with human PBMC engraftment when compared that in B-NDG mice or in B-NDG B2m KO mice plus. Therefore B-NDG MHC I/II DKO mice plus are more suitable mouse model for human PBMC engraftment into the immunodeficient mice. Values were expressed as mean ± SEM. 

Significantly reduced severity of GvHD induced with human PBMC engraftment in B-NDG MHC I/II DKO mice plus

from clipboard


Comparison of the peripheral blood leukocyte subpopulations in B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus after human PBMC engraftment. Five weeks old of female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were respectively engrafted intravenously with human PBMCs (5 × 106) from three healthy donors (Donor 1-3) on day 0 (n=5). Blood was collected weekly after engraftment of human PBMC for flow cytometric analysis. The reconstitution levels of all the leukocytes analyzed were similar among the three mice. 


Absolute number of reconstituted human immune cells  


from clipboard

Comparison of reconstitution levels of human PBMCs among B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus. Five-week-old female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were irradiated with 1.0 Gy and then engrafted intravenously with human PBMCs (5×106) from three healthy donors (Donor 1-3) on day 0 (n=6). Peripheral blood was taken weekly to analyze the reconstitution level of human immune cells. The experiment was ended 90 days after reconstitution. The results showed that regardless of which donor derived PBMCs were implanted, various types of human T cells could be reconstituted in B-NDG MHC I/II DKO mice plus. However, the numbers of all reconstituted cells in B-NDG MHC I/II DKO mice plus were lower than those in B-NDG mice and B-NDG B2m KO plus mice. Donor 3 has the most severe GvHD, and its human T cells and CD4 + T cells reconstitute the largest number.

A successful human PBMCs engrafted mouse model that can extend the window period of experiments

from clipboard

B-NDG MHC I/II DKO mice plus has a long life span and reduced severity of GvHD when engrafted with human PBMCs. B-NDG MHC I/II DKO mice plus were engrafted intravenously with human PBMCs (1×107) on day 0 (n=6). Survival rates of the mice were analyzed with Kaplan Meier survival curves. Body weight was measured twice a week. Clinical signs of GvHD were scored once a week. Euthanasia was implemented when the body weight decreased more than 20%. Meanwhile, the GvHD score of the mouse was recorded as 10. Results showed that all the mice can live up to 96 days. During this period, apart from weight loss, there were no other obvious symptoms of GvHD. Values were expressed as mean ± SEM. 

Frequency of reconstituted human immune cells  

from clipboard

Human PBMCs were successfully reconstituted in B-NDG MHC I/II DKO mice plus. B-NDG MHC I/II DKO mice plus were engrafted intravenously with human PBMCs (1×107) on day 0 (n=6). Peripheral blood was taken weekly to analyze the reconstitution level of human immune cells. The experiment was ended 112 days (16 weeks) after engraftment. A. Frequency of reconstituted human immune cells; B. Absolute cell number of reconstituted human immune cells. The results showed that two weeks after the reconstitution of human PBMCs in B-NDG MHC I/II DKO mice plus, the frequency and absolute cell number of CD45+ cells in peripheral blood began to increase, and a relatively stable level of reconstitution was maintained until the end point at 16 week. The frequency of reconstituted human T cells exceeded 90% from two weeks and continued to rise, eventually reaching nearly 100%. Reconstituted human T cells include CD4+T cells, CD8+T cells and Tregs. A small amount of DCs can also be detected. Human PD-1 is widely expressed on CD4+T cells and CD8+T cells. This indicates that B-NDG MHC I/II DKO mice plus is a powerful immunodeficient mouse model for reconstitution of the human immune system using human PBMCs.